Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1987 Nov;55(11):2841–2843. doi: 10.1128/iai.55.11.2841-2843.1987

Colonial dissociation and susceptibility to phagocytosis of Pseudomonas aeruginosa grown in a chamber implant model in mice.

N M Kelly 1, J L Battershill 1, S Kuo 1, J P Arbuthnott 1, R E Hancock 1
PMCID: PMC259987  PMID: 3117694

Abstract

Pseudomonas aeruginosa strains were grown in 1-cm plastic chambers sealed at both ends with porous Millipore filters and implanted in the peritonea of mice. Mucoid and nonmucoid strains of P. aeruginosa isolated from a patient with cystic fibrosis largely retained their phenotypes when grown for up to 1 year in this in vivo system, although colonial dissociation occurred, as observed in chronic lung infections of patients with cystic fibrosis. In the absence of added opsonins, P. aeruginosa M2 cells taken directly from the in vivo system were significantly more susceptible to phagocytosis than were the same P. aeruginosa cells after being washed in buffer. Phagocytosis of in vivo-grown P. aeruginosa cells could be further enhanced by using a porin protein F-specific monoclonal antibody.

Full text

PDF
2841

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Battershill J. L., Speert D. P., Hancock R. E. Use of monoclonal antibodies to protein F of Pseudomonas aeruginosa as opsonins for phagocytosis by macrophages. Infect Immun. 1987 Oct;55(10):2531–2533. doi: 10.1128/iai.55.10.2531-2533.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bergan T., Hoiby N. Epidemiological markers for Pseudomonas aeruginosa. 6. Relationship between concomitant non-mucoid and mucoid strains from the respiratory tract in cystic fibrosis. Acta Pathol Microbiol Scand Suppl. 1975 Dec;83(6):553–560. [PubMed] [Google Scholar]
  3. Coleman K. D., Wetterlow L. H. Use of implantable intraperitoneal diffusion chambers to study Bordetella pertussis pathogenesis: growth and toxin production in vivo. J Infect Dis. 1986 Jul;154(1):33–39. doi: 10.1093/infdis/154.1.33. [DOI] [PubMed] [Google Scholar]
  4. Day S. E., Vasli K. K., Russell R. J., Arbuthnott J. P. A simple method for the study in vivo of bacterial growth and accompanying host response. J Infect. 1980 Mar;2(1):39–51. doi: 10.1016/s0163-4453(80)91773-9. [DOI] [PubMed] [Google Scholar]
  5. Doggett R. G. Incidence of mucoid Pseudomonas aeruginosa from clinical sources. Appl Microbiol. 1969 Nov;18(5):936–937. doi: 10.1128/am.18.5.936-937.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Duncan J. L. Streptococcal growth and toxin production in vivo. Infect Immun. 1983 May;40(2):501–505. doi: 10.1128/iai.40.2.501-505.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Finn T. M., Arbuthnott J. P., Dougan G. Properties of Escherichia coli grown in vivo using a chamber implant system. J Gen Microbiol. 1982 Dec;128(12):3083–3091. doi: 10.1099/00221287-128-12-3083. [DOI] [PubMed] [Google Scholar]
  8. Hancock R. E., Mutharia L. M., Mouat E. C. Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F. Eur J Clin Microbiol. 1985 Apr;4(2):224–227. doi: 10.1007/BF02013602. [DOI] [PubMed] [Google Scholar]
  9. Hultgren S. J., Porter T. N., Schaeffer A. J., Duncan J. L. Role of type 1 pili and effects of phase variation on lower urinary tract infections produced by Escherichia coli. Infect Immun. 1985 Nov;50(2):370–377. doi: 10.1128/iai.50.2.370-377.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Mutharia L. M., Hancock R. E. Surface localization of Pseudomonas aeruginosa outer membrane porin protein F by using monoclonal antibodies. Infect Immun. 1983 Dec;42(3):1027–1033. doi: 10.1128/iai.42.3.1027-1033.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nicas T. I., Hancock R. E. Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediaminetetraacetate, polymyxin B, and gentamicin. J Bacteriol. 1980 Aug;143(2):872–878. doi: 10.1128/jb.143.2.872-878.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pacifico L., Chiesa C., Renzulli F., Cianfrano V., Chiavelli S., Midulla M. In vitro dissociative behavior of Pseudomonas aeruginosa. J Infect Dis. 1985 Oct;152(4):852–852. doi: 10.1093/infdis/152.4.852. [DOI] [PubMed] [Google Scholar]
  13. Phillips I. Identification of Pseudomonas aeruginosa in the clinical laboratory. J Med Microbiol. 1969 Feb;2(1):9–16. doi: 10.1099/00222615-2-1-9. [DOI] [PubMed] [Google Scholar]
  14. Speert D. P., Eftekhar F., Puterman M. L. Nonopsonic phagocytosis of strains of Pseudomonas aeruginosa from cystic fibrosis patients. Infect Immun. 1984 Mar;43(3):1006–1011. doi: 10.1128/iai.43.3.1006-1011.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Stieritz D. D., Holder I. A. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model. J Infect Dis. 1975 Jun;131(6):688–691. doi: 10.1093/infdis/131.6.688. [DOI] [PubMed] [Google Scholar]
  16. Thomassen M. J., Demko C. A., Boxerbaum B., Stern R. C., Kuchenbrod P. J. Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis. 1979 Dec;140(6):873–880. doi: 10.1093/infdis/140.6.873. [DOI] [PubMed] [Google Scholar]
  17. Zierdt C. H., Schmidt P. J. Dissociation in Pseudomonas aeruginosa. J Bacteriol. 1964 May;87(5):1003–1010. doi: 10.1128/jb.87.5.1003-1010.1964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Zierdt C. H., Williams R. L. Serotyping of Pseudomonas aeruginosa isolates from patients with cystic fibrosis of the pancreas. J Clin Microbiol. 1975 Jun;1(6):521–526. doi: 10.1128/jcm.1.6.521-526.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES